Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.68 |
| ▸ | PTPN11 | Q06124 | 6/20 | 0.54 |
| ▸ | NR0B2 | Q15466 | 3/20 | 0.54 |
| ▸ | RARA | P10276 | 3/20 | 0.52 |
| ▸ | RARG | P13631 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15232876 | 1.00 | RARB (0.71) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL30015150 | 0.88 | HDAC11 (0.76) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL404023 | 0.88 | HDAC11 (0.76) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL404024 | 0.88 | HDAC11 (0.76) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL23005221 | 0.85 | HDAC11 (0.58) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL23005222 | 0.85 | HDAC11 (0.58) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL29462780 | 0.83 | HDAC11 (0.65) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| Adarotene SCHEMBL403528 | 0.83 | RARB (1.00) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| Adarotene SCHEMBL29449480 | 0.83 | RARB (1.00) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| Adarotene SCHEMBL403527 | 0.83 | RARB (1.00) | RARBHDAC11HDAC2HDAC7HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11819484-B2 | Retinoid derivatives with antitumor activity | BIOGEM S.C. A R.L. (IT) | 2023-11-21 | — | — | US | disclosed |
| US-11819484-B2 | Retinoid derivatives with antitumor activity | BIOGEM S.C. A R.L. (IT) | 2023-11-21 | — | — | US | disclosed |
| US-11819484-B2 | Retinoid derivatives with antitumor activity | BIOGEM S.C. A R.L. (IT) | 2023-11-21 | — | — | US | disclosed |
| WO-2022229017-A1 | ADAMANTYL RETINOID DERIVATIVE WITH ANTICANCER ACTIVITY | BIOGEM S.C.A R.L. (IT) | 2022-11-03 | — | — | WO | disclosed |
| US-11364216-B2 | Retinoid derivatives with antitumor activity | BIOGEM S.C. A R.L. (IT) | 2022-06-21 | — | — | US | disclosed |
| US-11364216-B2 | Retinoid derivatives with antitumor activity | BIOGEM S.C. A R.L. (IT) | 2022-06-21 | — | — | US | disclosed |
| US-20220168252-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | BIOGEM S C A R L (IT) | 2022-06-02 | — | — | US | disclosed |
| US-20220168252-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | BIOGEM S C A R L (IT) | 2022-06-02 | — | — | US | disclosed |
| US-20210052530-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | BIOGEM S C A R L (IT) | 2021-02-25 | — | — | US | disclosed |
| US-20210052530-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | BIOGEM S C A R L (IT) | 2021-02-25 | — | — | US | disclosed |
| EP-2367781-B1 | RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES | SIGMA TAU IND FARMACEUTI (IT) | 2013-10-02 | — | — | EP | disclosed |
| US-8530517-B2 | Retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-09-10 | — | — | US | disclosed |
| US-20110312965-A1 | RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| EP-2367781-A1 | NEW RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010072727-A1 | NEW RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168252-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | RARA, RARB, RARG | RARB 2/4885HDAC11 1236/4885HDAC2 2813/4885 |
| US-11819484-B2 | Retinoid derivatives with antitumor activity | RARA, RARB, RARG | RARB 2/4885HDAC11 1236/4885HDAC2 2813/4885 |
| US-20210052530-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | RARA, RARB, RARG | RARB 2/4885HDAC11 1236/4885HDAC2 2813/4885 |
| US-20110312965-A1 | RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES | RARA, RARB, RBP1 | RARB 2/4885HDAC11 1387/4885HDAC2 3582/4885 |
| US-11364216-B2 | Retinoid derivatives with antitumor activity | RARA, RARB, RARG | RARB 2/4885HDAC11 1236/4885HDAC2 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.